Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations

J Clin Microbiol. 2004 Feb;42(2):862-6. doi: 10.1128/JCM.42.2.862-866.2004.

Abstract

A total of 76 patients discontinued treatment with didanosine plus hydroxyurea after 1 year of maintenance therapy. The greatest human immunodeficiency virus (HIV)-RNA rebounds were seen in 10 patients harboring an L74V mutation, and the presence of viruses with this mutation rapidly waned. In contrast, viral rebounds were significantly less pronounced (P < 0.01) in 12 subjects harboring thymidine-associated mutations; these mutations persisted in all instances. Thus, selection of an L74V mutation during didanosine therapy may compromise HIV replication in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / immunology
  • Amino Acid Substitution
  • Anti-HIV Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Didanosine / therapeutic use
  • Female
  • Genotype
  • HIV / genetics*
  • Humans
  • Hydroxyurea / therapeutic use
  • Male
  • Mutagenesis, Site-Directed
  • Mutation*
  • RNA, Viral / genetics
  • RNA, Viral / isolation & purification
  • Thymidine / genetics*
  • Time Factors
  • Viral Load*

Substances

  • Anti-HIV Agents
  • RNA, Viral
  • Didanosine
  • Thymidine
  • Hydroxyurea